Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modulation of Metabolic Index in Tailoring Treatment of Incurable Metastatic ColoRectal Cancer (CRC) Program 1.

NCT01843725 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT01843725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01843725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modulation of Metabolic Index in Tailoring Treatment of Incurable Metastatic ColoRectal Cancer (CRC) Program 1.
Lead sponsor
Jules Bordet Institute
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2013
Completion date
October 31, 2016
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic biliary cancers, metastatic breast cancers, metastatic colorectal cancers, metastatic gastric cancers, metastatic oesophageal cancers, metastatic pancreatic cancers